Clinical pearl! First-line tx w/ bio-originator or biosimilar ADA/ETA showed similar effectiveness & safety in long-term cohort of axSpA pts. Response to treatment was also similar between groups. Abs 0431 #ACR22 @RheumNow https://t.co/bGGXk51hIG https://t.co/PSsX3MpSXt
Links:
Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar…
http://ow.ly/Hgu550LvuwU
12-11-2022
